Conatus Pharmaceuticals (CNAT) Gains on WSJ Zika-Related Mention

August 29, 2016 11:58 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Conatus Pharmaceuticals (NASDAQ: CNAT) surges following WSJ mention related to Zika. Shares up 15%.

The article discusses liver-disease drug emricasan for use to quell the Zika virus, which Conatus holds several patents on.


Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment